Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

Summary

This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated dose in the patients.

Timeline

Start

2008-02-21

Primary completion

2009-06-16

Completion

2009-06-16

Publications

• Background Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H(3) receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr Alzheimer Res. 2013 Mar;10(3):240-51. doi: 10.2174/1567205011310030003.

Drugs

Indications